Patents Assigned to LXR Biotechnology, Inc.
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 6306398
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: October 23, 2001
    Assignee: LXR Biotechnology, Inc.
    Inventors: Ian Cyril Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof
    Patent number: 6015687
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 18, 2000
    Assignee: LXR Biotechnology Inc.
    Inventors: Michael C. Kiefer, Philip J. Barr
  • Compositions which inhibit apoptosis, methods of making the compositions and uses thereof
    Patent number: 6004579
    Abstract: The present invention provides compositions that inhibit apoptosis, methods for making the compositions, and methods of use thereof.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: December 21, 1999
    Assignee: LXR Biotechnology, Inc.
    Inventors: Ian C. Bathurst, Matthew W. Foehr, John G. Goddard, L. David Tomei, Philip J. Barr
  • Screening methods for the identification of compounds capable of abrogating BaK-BHRF-1 protein interactions
    Patent number: 5998131
    Abstract: The present invention provides methods for screening potential anti-viral therapeutic agents by monitoring their ability to disrupt the interaction between the BAK protein and a viral protein.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: December 7, 1999
    Assignee: LXR Biotechnology, Inc.
    Inventors: Philip J. Barr, Michael C. Kiefer
  • Apoptosis-modulating proteins, DNA encoding the proteins and methods of use thereof
    Patent number: 5770443
    Abstract: The present invention provides a novel family of apoptosis-modulating proteins. Nucleotide and amino acid residue sequences and methods of use thereof are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 23, 1998
    Assignee: LXR Biotechnology Inc.
    Inventors: Michael C. Kiefer, Philip J. Barr
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 5759548
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: October 7, 1994
    Date of Patent: June 2, 1998
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Method for quantitatively measuring apoptosis
    Patent number: 5750360
    Abstract: The invention encompasses methods of detecting and/or quantifying .epsilon.(.gamma.-glutamyl)lysine isodipeptide by catalytically releasing lysine, then measuring free lysine.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 12, 1998
    Assignee: LXR Biotechnology Inc.
    Inventors: Laszlo Fesus, Mauro Piacentini
  • Methods of identifying potentially therapeutically effective agents and cell strains for use therein
    Patent number: 5681703
    Abstract: The present invention is to a method of screening agents for potential therapeutic efficacy. The method comprises exposing a cell strain that is sensitive to apoptotic agents to known apoptotic agents and to a potential therapeutic agent. The cell strain is then cultured and cells are removed that display diminished adherence. The remaining, adherent, cells are then incubated in the presence of a proteinase to release proteinase sensitive cells. The proteinase sensitive cells are removed to yield proteinase resistant cells and the proteinase sensitive cells are counted. The proteinase resistant cells are then collected and counted. The agent is determined to have potential therapeutic efficacy if the ratio of proteinase sensitive cells to proteinase resistant cells changes relative to a control as a result of the presence of the agent.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 28, 1997
    Assignee: LXR Biotechnology Inc.
    Inventor: L. David Tomei
  • Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
    Patent number: 5663070
    Abstract: The invention provides soluble forms of the Fas (Apo-1 ) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 2, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Philip J. Barr, John P. Shapiro, Michael C. Kiefer
  • Soluble splice variant of the Fas (APO-1) antigen, Fas.DELTA.TM
    Patent number: 5652210
    Abstract: The invention provides soluble forms of the Fas (Apo-1) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: July 29, 1997
    Assignee: LXR Biotechnology, Inc.
    Inventors: Philip J. Barr, John P. Shapiro, Michael C. Kiefer
  • Methods of identifying potentially therapeutically effective agents and cell strains for use therein
    Patent number: 5637486
    Abstract: The present invention is to a method of screening agents for potential therapeutic efficacy. The method comprises exposing a cell strain that is sensitive to apoptotic agents to known apoptotic agents and to a potential therapeutic agent. The cell strain is then cultured and cells are removed that display diminished adherence. The remaining, adherent, cells are then incubated in the presence of a proteinase to release proteinase sensitive cells. The proteinase sensitive cells are removed to yield proteinase resistant cells and the proteinase sensitive cells are counted. The proteinase resistant cells are then collected and counted. The agent is determined to have potential therapeutic efficacy if the ratio of proteinase sensitive cells to proteinase resistant cells changes relative to a control as a result of the presence of the agent.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: June 10, 1997
    Assignee: LXR Biotechnology Inc.
    Inventor: L. David Tomei
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 5635187
    Abstract: The present invention is directed to methods of obtaining plant-derived delipidated extracts that inhibit apoptosis, the extracts obtained, compositions containing said extracts and methods of using said compositions. FIG. 11 is a bar graph which illustrates a lower incidence of diarrhea in rats treated with methotrexate and fed a diet of compositions of the claimed invention as compared to controls.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 3, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 5635186
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: June 3, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 5624672
    Abstract: The present invention is directed to methods of obtaining plant-derived delipidated extracts that inhibit apoptosis, the extracts obtained, compositions containing said extracts and methods of using said compositions. The figure is a bar graph which illustrates a lower incidence of diarrhea in rats treated with methotrexate and fed a diet of compositions of the claimed invention as compared to controls.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 29, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Cell strains for use in identifying potentially therapeutically effective agents
    Patent number: 5620888
    Abstract: The present invention provides cell strains suitable for use in screening agents for potential therapeutic efficacy. The cell strains retain responsiveness to apoptosis inducers and inhibitors.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 15, 1997
    Assignee: LXR Biotechnology, Inc.
    Inventor: L. David Tomei
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 5620885
    Abstract: The present invention is to methods of obtaining plant-derived compositions that-inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: April 15, 1997
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr
  • Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
    Patent number: 5567425
    Abstract: The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: October 22, 1996
    Assignee: LXR Biotechnology Inc.
    Inventors: Ian C. Bathurst, John D. Bradley, L. David Tomei, Philip J. Barr